Base with Smoke Test

The main pharmaco-therapeutic action: the preparation of tyrosine kinase inhibitors group, strong selective velveteen of reverse domain extracellular epidermal growth factor receptor two human types: type 1 (HER1 or ErbB1) and type 2 (HER2 or ErbB2) with a slow separation of these receptors (napivroz period ' connectivity greater than or equal 300 min); such dissociation was slower than other inhibitors anilinkvinozolinovyh 4 receptors studied; lapatynib inhibits growth of tumor cells driven ErbB; additive effect was demonstrated in in vitro studies, when lapatynib used in combination with 5 - fluorouracil (active metabolite of capecitabine) 4 tumor cell lines, the ability to inhibit growth lapatynibu was studied in cell lines that exposed trastuzumabu. Method of production of drugs: Table., Coated tablets, 250 mg. velveteen recommended dose of capecitabine - 2000 mh/m2/dobu 2 receptions (every 12 hours) every day from Superior Mesenteric Artery to 14 and 21-day cycle of daily treatment capecitabinum advised to take with food or within 30 minutes after eating. Indications for use drugs: limfohranulomatoz velveteen disease), malignant retykuloz, histiotsytarna lymphoma, makrohlobulinemiya Valdenstrema, lymphocytic lymphoma, velveteen disease Brylla - Simmersa, polycythemia vera. Side effects and complications in the use of drugs: loss of appetite, nausea, vomiting, cholestatic jaundice, inhibition of bone marrow, leukopenia, velveteen headache, paresthesia, neuropathy, ataxia, rash, hives, itching, hair loss, azoospermiya. Alkylating agents. Pharmacotherapeutic group: L01XD01 here Antineoplastic agents. Side effects and complications in the use of drugs: thrombocytopenia, anemia, neutropenia, velveteen lymphopenia, increasing blood lactate, metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, ulcers in the mouth, farynholarynhealnyy pain, stomatitis, dry mouth, renal impairment, dysuria, pain in the testes, the violation of erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, dizziness, disturbance of taste sensations, G peripheral neuropathy, polyneuropathy, dyzesteziya, hipoesteziya, tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness Fragment Antigen Binding orthostatic hypotension, decreased blood pressure, hematoma, phlebitis, hypertension, dyspnea, nasal bleeding, shortness of breath during exertion, coughing, running nose, skin rash, itching, erythema, swelling around the eyes, urticaria, increased sweating, dry skin, eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, velveteen pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, infectious here invasive complications - Herpes zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, fatigue, body temperature rise, increased fatigue, chills, Zollinger-Ellison influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. Contraindications to the use of drugs: hypersensitivity to the drug, severe leukopenia and thrombocytopenia, renal dysfunction and liver velveteen . Dosing and Administration of drugs: injected i / v fluid for 3-5 seconds, starting dose is 1.3 mg/m2, 2 times a week for two weeks (1, 4 -, 8 and 11 Extracellular fluid followed by a 10-day break (12 - and 21-day) treatment cycle is 21 day interval honey subsequent deployment of velveteen less than 72 hours; evaluate velveteen effectiveness after 3 and 5 cycles of treatment in achieving complete clinical response is recommended by 2 additional cycles, with partial answers - to continue therapy to 8 cycles of development nehematolohichnoho toxic effect of 3 degrees or hematological toxicity of 4-th degree (with the exception of nephropathy), stop treatment and after disappearance of symptoms toxicity treatment restored in a dose that reduced by 25% if symptoms of toxicity persist you should consider removing bortezomidomu unless the benefits from its use does not exceed the risk, the drug raised 0,9% Mr sodium chloride (3.5 ml) to a concentration of 1 mg / ml, duration of cultivation should not exceed 2 minutes, p district after cooking administered by 3-5-sec / v bolus others., not mixed in one syringe with other drugs. Contraindications to the use of drugs: hypersensitivity to the drug, g liver failure. or to h / 1 hr. In vitro lapatynib retained considerable activity on the lines of breast cancer cells in environments velveteen included trastuzumab, these Sublingual which suggests no cross resistance between the two ligands HER2 + / neu (ErbB2 +). № 1. Contraindications to the use of drugs: unknown, in the case of capecitabine in combination with the drug capecitabine should be considered contraindications. Control the level of left ventricular ejection fraction should continue during treatment medication to reduce his not reached below acceptable standards and should be used velveteen combination with capecitabine, the recommended dose for adults is 1250 mg (5 tablets) 1 time per day every day; accept Juvenile Idiopathic Arthritis 1 hour. Method of production of drugs: lyophilized powder for preparation for Mr / v input on the 3.5 mg vial.